Compared with patients with other breast cancer subtypes, TNBC patients have higher PD-L1 expression and more tumor-infiltrating lymphocytes (TILs).5 Therefore, with the success of immune checkpoint inhibitor (ICI) therapy in various malignancies,6–8 PD-L1-targeting strategy has been investigated in patients with TNBC. Here, CD274 is linked to neoplasm.